Document is current
Any future updates will be listed below
-
Authors
Maughan, Benjamin L.
Liu, Yanfang
Mundle, Suneel
Wang, Xiayi
Nematian-Samani, Mehregan
Karsh, Lawrence I. https://orcid.org/0000-0002-3095-8303
-
Funding
Funding for this research was provided by:
Janssen Global Services, LLC
- License Information
-
More Information
Article History
Received: 23 May 2024
Revised: 26 November 2024
Accepted: 9 December 2024
First Online: 20 December 2024
Competing interests
: LIK owns stock in Swan Valley Medical, has received honoraria from Astellas, Astra-Zeneca, Abbvie, Bayer, Dendreon, Janssen, Merck, Myovant, Pfizer, and Sanofi, has received financial compensation as a paid consultant/advisor to Astellas, Astra-Zeneca, Abbvie, Bayer, Bristol Myers Squibb, Bayer, Ferring, Dendreon, Janssen, Merck, Myovant, Pfizer, and Sanofi, and has received financial compensation to participate in speakers bureaus for Astellas, Astra-Zeneca, Bayer, Dendreon, Janssen, Merck, Myovant, and Pfizer. He has received institutional funding from Janssen, Bayer, Bristol Myers Squibb, Dendreon, Epizyme, Astellas, Pfizer, Astra Zeneca, BioExcel, Vaxiion, Kdx, OncoCell, Neuspera, Myovant, FKD, and Cleveland Diagnostics. BLM has received financial compensation as a paid consultant/advisor to Abbive, Pfizer, AVEO oncology, Janssen, Astellas, Bristol-Myers Squibb, Clovis, Tempus, Merck, Exelixis, Bayer Oncology, Lilly, Sanofi, Telix and Peloton Therapeutics; Huntsman Cancer Institute has received research funding from Exelixis, Bavarian-Nordic, Clovis and Bristol-Myers Squibb on his behalf. YL, SM, XW, and MN-S are employees of Johnson & Johnson LLC. YL and SM hold stock/shares in Johnson & Johnson LLC.
